Respiratory care assessment of smoking cessation drug therapy includes
1)monitoring abstinence rates at intervals such as 3,6,or 12 months.
2)monitoring for symptoms of nicotine overdose.
3)counseling and support throughout treatment for smoking cessation.
4)assessing patients for weight gain and encouraging an exercise program.

Question

Quizplus · Accepted Answer

The primary outcome of interest with smoking cessation drug therapy is success in quitting over the long-term.
•Monitor abstinence rates at intervals such as 3,6,or 12 months.
• Monitor for symptoms of nicotine overdosage (possible if subjects continue smoking while using nicotine substitutes),such as nausea,salivation,abdominal pain,vomiting,diarrhea,cold sweat,headache,dizziness,disturbed vision and hearing,mental confusion,or marked weakness.
•Assess bupropion use for improvement in emotional attitude,including reduction in irritability,anxiety,difficulty in concentrating,or depression.
•Assess varenicline use for improvement in nicotine withdrawal symptoms.
•Assess clonidine and nortriptyline for possible use as smoking cessation aids.
•Monitor clonidine for adverse actions related to cardiovascular status.
•Monitor nortriptyline for change in emotional state.
•Assess patients for weight gain,and encourage an exercise program to prevent relapse caused by desire for appetite control.
•Continue to provide counseling and support throughout treatment for smoking cessation.

Respiratory Care Assessment of Smoking Cessation Drug Therapy Includes